ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
NICE rejects adjuvant use of Perjeta post-surgery
pharmatimes
June 21, 2018The National Institute for Health and Care Excellence says adjuvant use of Roche’s breast cancer drug Perjeta in patients who have had surgery is not cost effective for the NHS.
Pharma Sources Insight January 2025
